Latham & Watkins represented Alphatec in the transaction. Alphatec Holdings, Inc. (Alphatec) announced the close of an asset-based revolving credit facility in the maximum aggregate amount...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Gossamer Bio in the transaction. Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutics in...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Ligand in the transaction, while Weil, Gotshal & Manges represented APAC. Ligand Pharmaceuticals Incorporated has announced the signing of a definitive merger...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented the underwriters in the offering. Travere Therapeutics, Inc. executed its offering of US$275 million aggregate principal amount of 2.25% convertible senior notes due...
You must be a Standard 1 Year member to access this content.
Covington represented UCB, while Latham & Watkins represented Zogenix on the deal. Fried Frank acted as counsel to BofA Securities and SVB Leerink as financial advisors to...
You must be a Standard 1 Year member to access this content.
Cleary Gottlieb Steen & Hamilton represented GlobalFoundries in the offering, while Latham & Watkins represented the underwriters. GlobalFoundries® (GF®), a global leader in feature-rich semiconductor manufacturing, announced...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Alphatec Holdings in the transaction. Alphatec Holdings, Inc. (Nasdaq: ATEC) has announced the pricing of its offering of US$275,000,000 aggregate principal amount of...
You must be a Standard 1 Year member to access this content.
Latham & Watkins represented Icosavax, while Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal. Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its...
You must be a Standard 1 Year member to access this content.
Latham & Watkins LLP and Wilson Sonsini Goodrich & Rosati represented Erasca in the transaction. Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Janux Therapeutics, Inc. on the deal, while Latham & Watkins LLP represented the underwriters. Janux Therapeutics, Inc., a biopharmaceutical company...
You must be a Standard 1 Year member to access this content.
